News from oncolytics biotech inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 19, 2021, 09:44 ET Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, November 5, 2021, at 8:00 a.m. ET to discuss a corporate update and...

Nov 06, 2020, 07:00 ET Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Wednesday, November 11, 2020, at 5:00 pm ET to discuss a corporate update and...

Oct 19, 2020, 07:00 ET Oncolytics Biotech® Appoints Richard Vile, Ph.D., to its Scientific Advisory Board

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the appointment of Richard Vile, Ph.D., to its Scientific Advisory Board (SAB). Dr. Vile, a Professor of Immunology at the Mayo...

Jul 29, 2020, 07:00 ET Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Tuesday, August 4, 2020, at 4:30 pm ET to discuss a corporate update and...

May 29, 2020, 07:00 ET Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an electronic-poster...

May 26, 2020, 07:00 ET Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an electronic-poster...

May 08, 2020, 07:00 ET Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the the voting results from its Annual General...

May 08, 2020, 07:00 ET Oncolytics Biotech® Reports 2020 First Quarter Financial Results and Operational Highlights

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational...

May 04, 2020, 07:00 ET Oncolytics Biotech® to Present Clinical Findings of Pelareorep-Induced Immune Response in Breast Tumors at the ESMO Breast Cancer Virtual Meeting

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an abstract for an...

Jan 13, 2020, 07:00 ET Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) (TSX: ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today provided a recap of a Key Opinion Leader...

Dec 27, 2017, 07:00 ET Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas

CALGARY and SAN DIEGO, CA, Dec. 27, 2017 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, also known as pelareorep, an...

Dec 05, 2017, 07:00 ET Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer

Proposed phase 3 study design is found acceptable and can form the basis of a Marketing Authorization Application (MAA) Feedback continues to support our focus on HR+/HER2- patients that reported a...

Dec 04, 2017, 07:00 ET Oncolytics Biotech® to Present at the Oncolytic Virotherapy Summit

Dr. Matt Coffey, Oncolytics' President & Chief Executive Officer, to present on the clinical progress of using reovirus as an immuno-oncology viral agent to treat cancer CALGARY and SAN DIEGO, CA,...

Nov 30, 2017, 07:00 ET Oncolytics Biotech® Establishes Scientific Advisory Board Focused on REOLYSIN® Registration Study in Metastatic Breast Cancer

CALGARY and SAN DIEGO, Nov. 30, 2017 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, also known as pelareorep, an...

Nov 16, 2017, 17:00 ET Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®

Regional license covers China, Hong Kong, Macau, Singapore, South Korea and Taiwan Oncolytics to receive upfront, licensing fee and milestone payments to support phase 3 registration study of USD $21....

Nov 08, 2017, 07:00 ET Oncolytics Biotech® Inc. Announces 2017 Third Quarter Results

CALGARY, and SAN DIEGO, CA, Nov. 8, 2017 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, an intravenously delivered...

Nov 02, 2017, 07:00 ET Oncolytics Biotech® Appoints Deborah Brown to Board of Directors

CALGARY and SAN DIEGO, CA, Nov. 2, 2017 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN®, an intravenously delivered...

Oct 11, 2017, 07:00 ET Oncolytics Biotech® to Present at the 2017 BIO Investor Forum

Presenting clinical data of REOLYSIN® in metastatic breast cancer and the Company's strategic objectives CALGARY and SAN DIEGO, Oct. 11, 2017 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX:...

Sep 19, 2017, 07:00 ET Oncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers Conference

Dr. Andres Gutierrez, Oncolytics' Chief Medical Officer, to present on the clinical progress and robust safety findings of using reovirus as an immuno-oncology viral agent to treat cancer CALGARY and ...

Sep 18, 2017, 07:00 ET Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast Cancer

Outcome supports focus on HR+/HER2- patient group that reported an effective doubling of median overall survival from 10.8 to 21.0 months CALGARY and SAN DIEGO, Sept. 18, 2017 /CNW/ - Oncolytics...

Sep 14, 2017, 07:00 ET Oncolytics Biotech® Announces First Patient Treated in MUK eleven Study

CALGARY and SAN DIEGO, Sept. 14, 2017 /CNW/ - Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN® (pelareorep), a first-in-class,...

Sep 11, 2017, 07:00 ET Oncolytics Biotech® Announces the Presentation of REOLYSIN® Clinical Data at ESMO 2017 Congress

Additional randomized phase 2 data in metastatic breast cancer demonstrates doubling of overall survival in Hormone Receptor Positive (ER+PR+)/HER2- patients Largest immuno-oncolytic virus safety...

Aug 03, 2017, 07:00 ET Oncolytics Biotech® Inc. Announces 2017 Second Quarter Results

CALGARY and SAN DIEGO, CA, Aug. 3, 2017 /CNW/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced its financial results and operational highlights for the...

Aug 01, 2017, 07:00 ET Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference

CALGARY, AB and SAN DIEGO, CA, Aug. 1, 2017 /CNW/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) will present at the Canaccord Genuity 37th Annual Growth Conference....

Jul 26, 2017, 07:00 ET Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 Congress

Announces end-of-phase 2 meeting with the U.S. Food and Drug Administration CALGARY and SAN DIEGO, July 26, 2017 /CNW/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF)...